association

Full identifier: http://purl.org/np/RA9tRxBa8bjD8FfaqNArT4UOhPEtG8MFlXGWz86Davw5Q#association

Assigned to 1 class:

Minted in Nanopublication

 RA9tRxBa8b comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RA9tRxBa8b...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "esomeprazole magnesium delayed release capsules usp are a proton pump inhibitor indicated for the following treatment of gastroesophageal reflux disease gerd 1 1 risk reduction of nsaid associated gastric ulcer 1 2 eradication to reduce the risk of duodenal ulcer recurrence h pylori 1 3 pathological hypersecretory conditions including zollinger ellison syndrome 1 4 healing of erosive esophagitis esomeprazole magnesium delayed release capsules usp are indicated for the short term treatment 4 to 8 weeks in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis for those patients who have not healed after 4 to 8 weeks of treatment an additional 4 to 8 week course of esomeprazole magnesium delayed release capsules usp may be considered maintenance of healing of erosive esophagitis esomeprazole magnesium delayed release capsules usp are indicated to maintain symptom resolution and healing of erosive esophagitis controlled studies do not extend beyond 6 months symptomatic gastroesophageal reflux disease esomeprazole magnesium delayed release capsules usp are indicated for short term treatment 4 to 8 weeks of heartburn and other symptoms associated with gerd in adults and children 1 year or older esomeprazole magnesium delayed release capsules usp are indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy in patients at risk for developing gastric ulcers patients are considered to be at risk due to their age 6 and or documented history of gastric ulcers controlled studies do not extend beyond 6 months triple therapy esomeprazole magnesium delayed release capsules usp plus amoxicillin and clarithromycin esomeprazole magnesium delayed release capsules usp in combination with amoxicillin and clarithromycin is indicated for the treatment of patients with infection and duodenal ulcer disease active or history of within the past 5 years to eradicate eradication of has been shown to reduce the risk of duodenal ulcer recurrence h pylori h pylori h pylori see dosage and administration and clinical studies 2 14 in patients who fail therapy susceptibility testing should be done if resistance to clarithromycin is demonstrated or susceptibility testing is not possible alternative antimicrobial therapy should be instituted see clinical pharmacology and the prescribing information for clarithromycin 12 4 esomeprazole magnesium delayed release capsules usp are indicated for the long term treatment of pathological hypersecretory conditions including zollinger ellison syndrome" .
This is the identifier for this whole nanopublication. http://purl.org/np/RA9tRxBa8b... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-06-30T08:56:25.487+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RA9tRxBa8b... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RA9tRxBa8b... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RA9tRxBa8b... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .
This is a local identifier minted within the nanopublication. http://purl.org/np/RA9tRxBa8b...#sig sig http://purl.org/nanopub/x/hasSignatureTarget has as target This is the identifier for this whole nanopublication. http://purl.org/np/RA9tRxBa8b... this nanopublication .
This is a local identifier minted within the nanopublication. http://purl.org/np/RA9tRxBa8b...#sig sig http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal) "RSA" .

Leoni Bücken, 30 Jun 2021, 06:56:25 UTC

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-30T06:56:25.487Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
esomeprazole magnesium delayed release capsules usp are a proton pump inhibitor indicated for the following treatment of gastroesophageal reflux disease gerd 1 1 risk reduction of nsaid associated gastric ulcer 1 2 eradication to reduce the risk of duodenal ulcer recurrence h pylori 1 3 pathological hypersecretory conditions including zollinger ellison syndrome 1 4 healing of erosive esophagitis esomeprazole magnesium delayed release capsules usp are indicated for the short term treatment 4 to 8 weeks in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis for those patients who have not healed after 4 to 8 weeks of treatment an additional 4 to 8 week course of esomeprazole magnesium delayed release capsules usp may be considered maintenance of healing of erosive esophagitis esomeprazole magnesium delayed release capsules usp are indicated to maintain symptom resolution and healing of erosive esophagitis controlled studies do not extend beyond 6 months symptomatic gastroesophageal reflux disease esomeprazole magnesium delayed release capsules usp are indicated for short term treatment 4 to 8 weeks of heartburn and other symptoms associated with gerd in adults and children 1 year or older esomeprazole magnesium delayed release capsules usp are indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy in patients at risk for developing gastric ulcers patients are considered to be at risk due to their age 6 and or documented history of gastric ulcers controlled studies do not extend beyond 6 months triple therapy esomeprazole magnesium delayed release capsules usp plus amoxicillin and clarithromycin esomeprazole magnesium delayed release capsules usp in combination with amoxicillin and clarithromycin is indicated for the treatment of patients with infection and duodenal ulcer disease active or history of within the past 5 years to eradicate eradication of has been shown to reduce the risk of duodenal ulcer recurrence h pylori h pylori h pylori see dosage and administration and clinical studies 2 14 in patients who fail therapy susceptibility testing should be done if resistance to clarithromycin is demonstrated or susceptibility testing is not possible alternative antimicrobial therapy should be instituted see clinical pharmacology and the prescribing information for clarithromycin 12 4 esomeprazole magnesium delayed release capsules usp are indicated for the long term treatment of pathological hypersecretory conditions including zollinger ellison syndrome
Leoni Bücken
2021-06-30T06:56:25.487Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-30T06:56:25.487Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-30T06:56:25.487Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-30T06:56:25.487Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-30T06:56:25.487Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-30T06:56:25.487Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-30T06:56:25.487Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)